BOSTON--(BUSINESS WIRE)--New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today the appointment of Shane Johnson as Chief Commercial Officer. Shane will be responsible for leading the company's commercialization activities. Shane has more than 25 years of med tech commercial experience, having previously served as Vice President of Sales at Aerin Medical, Vertiflex, and Kyphon.
“We are excited to welcome Shane to New View Surgical as we look forward to launching our novel VisionPort™ System into the US market later this year,” said Bryce Klontz, Chief Executive Officer of New View Surgical. “Shane’s leadership and broad experience in launching new and innovative devices will be essential to the success of our initial market release of the VisionPort System later this year.”
Shane has a strong track record of success in the minimally invasive med tech industry, having built commercial capabilities, leading sales, operations, and marketing teams and cultivating strong key opinion leader relationships across multiple product lines and point of care environments. Of Shane’s 25 years of medical device experience, he has served the last 18 in commercial executive leadership roles. Shane joins us from Aerin Medical where he spent the last 5 years as the Vice President of Sales, creating the strategy and building the organization for the launch of two innovative products within the ENT space. Prior to Aerin Medical, Shane served as the VP of Sales at Vertiflex where he was the first commercial hire resulting in a $465M acquisition by Boston Scientific. Nearly half of his career was spent at Kyphon in progressive sales leadership roles, with his last role in the organization as a Vice President of Sales helping drive to a successful IPO and ultimately a $3.9B acquisition by Medtronic.
“New View Surgical is taking the bold step to reimagine laparoscopic visualization and create exceptional clinical and economic value,” commented Shane. “I joined New View Surgical because of the unique opportunity to redefine how minimally invasive surgery can be accomplished. It is rare to find a product that can provide increased value across multiple stakeholders including the patient, physician and site of service. The vision that CEO, Bryce Klontz and the Board has created, along with the enormous market opportunity, positions New View Surgical to drive a paradigm shift within the minimally invasive surgical space.”
The VisionPort™ System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder and allows multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, making state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity.
About New View Surgical, Inc.
New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort System combines multiple imaging and access devices into one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical, operational, and financial advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.